Literature DB >> 12773665

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

Catherine Roche-Lestienne, Jean-Luc Laï, Stéphane Darré, Thierry Facon, Claude Preudhomme.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12773665     DOI： 10.1056/NEJMc035089

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  30 in total

Review 1.  The influence of subclonal resistance mutations on targeted cancer therapy.

Authors:  Michael W Schmitt; Lawrence A Loeb; Jesse J Salk
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

2.  Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.

Authors:  Ian J Griswold; Mary MacPartlin; Thomas Bumm; Valerie L Goss; Thomas O'Hare; Kimberly A Lee; Amie S Corbin; Eric P Stoffregen; Caitlyn Smith; Kara Johnson; Erika M Moseson; Lisa J Wood; Roberto D Polakiewicz; Brian J Druker; Michael W Deininger
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

3.  The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.

Authors:  Franck E Nicolini; Amr R Ibrahim; Simona Soverini; Giovanni Martinelli; Martin C Müller; Andreas Hochhaus; Inge H Dufva; Dong-Wook Kim; Jorge Cortes; Michael J Mauro; Charles Chuah; Hélène Labussière; Stéphane Morisset; Catherine Roche-Lestienne; Eric Lippert; Sandrine Hayette; Senaka Peter; Wei Zhou; Véronique Maguer-Satta; Mauricette Michallet; John Goldman; Jane F Apperley; François-Xavier Mahon; David Marin; Gabriel Etienne
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

4.  Systematic assessment of analytical methods for drug sensitivity prediction from cancer cell line data.

Authors:  In Sock Jang; Elias Chaibub Neto; Juistin Guinney; Stephen H Friend; Adam A Margolin
Journal:  Pac Symp Biocomput       Date:  2014

5.  Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias.

Authors:  Michael W Schmitt; Justin R Pritchard; Scott M Leighow; Bella I Aminov; Lan Beppu; Daniel S Kim; J Graeme Hodgson; Victor M Rivera; Lawrence A Loeb; Jerald P Radich
Journal:  Clin Cancer Res       Date:  2018-07-24       Impact factor: 12.531

6.  Modeling the Subclonal Evolution of Cancer Cell Populations.

Authors:  Diego Chowell; James Napier; Rohan Gupta; Karen S Anderson; Carlo C Maley; Melissa A Wilson Sayres
Journal:  Cancer Res       Date:  2017-11-29       Impact factor: 12.701

7.  Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.

Authors:  Xiaoyan Jiang; Donna Forrest; Franck Nicolini; Ali Turhan; Joelle Guilhot; Calvin Yip; Tessa Holyoake; Heather Jorgensen; Karen Lambie; Kyi Min Saw; Emily Pang; Ranko Vukovic; Paeta Lehn; Ashley Ringrose; Miao Yu; Ryan R Brinkman; Clay Smith; Allen Eaves; Connie Eaves
Journal:  Blood       Date:  2010-06-23       Impact factor: 22.113

8.  Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment.

Authors:  Yosuke Minami; Tomohiro Kajiguchi; Akihiro Abe; Toshihito Ohno; Hitoshi Kiyoi; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-10-22       Impact factor: 2.490

9.  Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.

Authors:  S A Bright; A M McElligott; J W O'Connell; L O'Connor; P Carroll; G Campiani; M W Deininger; E Conneally; M Lawler; D C Williams; D M Zisterer
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

10.  Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR.

Authors:  Masahide Yamamoto; Kazuhiko Kakihana; Kazuteru Ohashi; Toshikazu Yamaguchi; Kenichi Tadokoro; Hideki Akiyama; Hisashi Sakamaki
Journal:  Int J Hematol       Date:  2009-04-03       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.